Burjeel treats first Camizestrant patient after UAE approval

Burjeel Cancer Institute gave Camizestrant to the world’s first clinical-care patient on 17 June 2026, six days after UAE approval.

The case matters most for medical directors, COOs and CIOs because eligible advanced breast cancer patients may now need serial molecular testing before scans or symptoms show progression. For Abu Dhabi providers, that puts laboratory capacity, tumour board review, pharmacy access and payer documentation inside one pathway.

Why the first case matters

The patient is a woman in her forties with advanced breast cancer and an ESR1 gene mutation, according to a 17 June 2026 Abu Dhabi Media Office statement. The Department of Health – Abu Dhabi (DOH) said the mutation was found through circulating tumour DNA, or ctDNA, a blood-based method used to detect molecular changes linked to endocrine therapy resistance.

Camizestrant is the active ingredient in AstraZeneca’s Etcamah, an oral selective estrogen receptor degrader and full estrogen receptor antagonist. The Emirates Drug Establishment (EDE) approved Etcamah on 11 June 2026 for patients with advanced or metastatic breast cancer whose disease has an ESR1 mutation. Gulf News reported that the UAE was the first country to approve the treatment.

• 6 days separated EDE approval and the first clinical-care dose at Burjeel Cancer Institute.
• 56% was the reported reduction in risk of disease progression or death in the relevant SERENA-6 Phase III trial comparison.
• ESR1 mutation status is the access point for the patient group described by EDE and DOH.
• ctDNA monitoring is the diagnostic trigger before radiological or clinical progression.

What operators need to build

For oncology centres, the decision changes daily workflow. A patient on endocrine therapy may need repeat ctDNA testing, molecular review and a treatment switch before a conventional progression event. That affects medical oncology protocols, laboratory turnaround times and pharmacy formulary governance in 2026.

The clinical case is supported by the global SERENA-6 Phase III trial. DOH said the trial found that switching patients with an ESR1 mutation detected through ctDNA monitoring to Camizestrant reduced the risk of disease progression or death by 56% compared with continued conventional endocrine therapy.

We look forward to strengthening collaboration with partners across the UAE to help improve treatment outcomes for eligible patients.
Sameh El Fangary, Gulf Country President, AstraZeneca

CIOs should treat this as an interoperability issue. ctDNA results need to move from laboratory systems into the electronic medical record, then into tumour board workflows and prescribing controls. COOs should check whether consent, sample logistics and molecular review can be completed through a defined pathway.

The UAE access question

DOH regulates Abu Dhabi and Al Ain healthcare providers. The Dubai Health Authority (DHA) regulates Dubai facilities, while the Ministry of Health and Prevention (MOHAP) oversees federal health policy and healthcare activity in the Northern Emirates. EDE approval creates the national drug access framework, but facility adoption will still depend on each emirate’s licensing, prescribing and reimbursement controls.

For CEOs and CFOs, the commercial question is narrower than the first-dose headline. The addressable market is limited to advanced or metastatic breast cancer patients with an ESR1 mutation, but the pathway may raise demand for molecular testing, oncology pharmacy services and specialist breast cancer programmes. Providers with established ctDNA access and tumour boards will have a shorter route to adoption in 2026.

The next test is payer behaviour. If insurers reimburse serial ctDNA monitoring and the oral therapy without prolonged case review, the Abu Dhabi case could become a practical template for precision oncology across the UAE. If approval remains episodic, uptake will concentrate in larger cancer centres with the administrative capacity to manage high-cost oncology authorisations.